{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T09:01:10Z","timestamp":1788080470565,"version":"build-2784847793"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease characterized by late-stage manifestation and relative resistance to standard therapies. Challenges with early detection and a paucity of effective therapies lead to one of the lowest 5-year survival rates among all cancers. Individuals around 50 years and over presenting with new onset diabetes (NOD) have a higher risk for PDAC diagnosis within 3 years of diabetes onset compared to the rest of the population. In this review, we contextualize NOD within other types of diabetes presentations such as type 1 diabetes (T1D), type 2 diabetes (T2D), and type 3 diabetes (T3cD), unravel the bidirectional relationship between diabetes and PDAC, and highlight potential biomarkers that may distinguish PDAC-associated diabetes from other predominant types of diabetes. Although practical applications of NOD currently fall short from being clinically actionable, clinical trials are underway to stratify NOD patients with PDAC-associated diabetes. Ultimately, these efforts could offer the rationale to implement early detection screening strategies to this subgroup of PDAC patients.<\/jats:p>","DOI":"10.3389\/fgstr.2025.1645459","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:42:52Z","timestamp":1768196572000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["New-onset diabetes as an emerging risk group for early detection of pancreatic cancer: current evidence, clinical challenge, and future directions"],"prefix":"10.3389","volume":"4","author":[{"given":"Lan Valerie","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Karasinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa G. P.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Loree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Renouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2016.09.008","article-title":"Molecular pathogenesis of pancreatic cancer","volume":"144","author":"Grant","year":"2016","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/BF02712816","article-title":"Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage","volume":"7","author":"Porta","year":"2005","journal-title":"Clin Transl Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3390\/cancers15041331","article-title":"Challenges in diagnosis and treatment of pancreatic exocrine insufficiency among patients with pancreatic ductal adenocarcinoma","volume":"15","author":"Lan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/1471-2407-9-255","article-title":"Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function","volume":"9","author":"Bachmann","year":"2009","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12307","article-title":"Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer","volume":"9","author":"Kays","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3322\/caac.21446","article-title":"Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening","volume":"68","author":"Smith","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2011.021","article-title":"The clinical utility of serum CA 19\u20139 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal","volume":"3","author":"Ballehaninna","year":"2012","journal-title":"J Gastrointest Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.10232","article-title":"Screening for pancreatic cancer: US preventive services task force reaffirmation recommendation statement","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198904000-00020","article-title":"New-onset diabetes mellitus as a harbinger of pancreatic carcinoma. A case report and literature review","volume":"11","author":"Rosa","year":"1989","journal-title":"J Clin Gastroenterol"},{"key":"B13","first-page":"298","article-title":"Collaborative studies in the diagnosis of pancreatic cancer","volume":"6","author":"Moossa","year":"1979","journal-title":"Semin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2005.05.007","article-title":"Probability of pancreatic cancer following diabetes: a population-based study","volume":"129","author":"Chari","year":"2005","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16503","article-title":"Predicting the risk of pancreatic cancer in women with new-onset diabetes mellitus","volume":"39","author":"Ali","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac728","article-title":"Difference of risk of pancreatic cancer in new-onset diabetes and long-standing diabetes: A population-based cohort study","volume":"108","author":"Lee","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.lanwpc.2022.100596","article-title":"Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer: Results from a longitudinal cohort and mendelian randomization study","volume":"30","author":"Shen","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02693-9","article-title":"Predicting the risk of pancreatic cancer in adults with new-onset diabetes: development and internal-external validation of a clinical risk prediction model","volume":"130","author":"Clift","year":"2024","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001897","article-title":"Machine learning predicts patients with new-onset diabetes at risk of pancreatic cancer","volume":"58","author":"Khan","year":"2024","journal-title":"J Clin Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318238348c","article-title":"New-onset diabetes patients need pancreatic cancer screening","volume":"46","author":"Lee","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70388","article-title":"Predicting pancreatic cancer in new-onset diabetes cohort using a novel model with integrated clinical and genetic indicators: A large-scale prospective cohort study","volume":"13","author":"Sun","year":"2024","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.07.010","article-title":"The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study","volume":"47","author":"Ben","year":"2011","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002052","article-title":"A clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes","volume":"152","author":"Boursi","year":"2017","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1038\/ctg.2015.44","article-title":"Predictors for pancreatic cancer diagnosis following new-onset diabetes mellitus","volume":"6","author":"Munigala","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/jnci\/djy090","article-title":"Pancreatic cancer following incident diabetes in african americans and latinos: the multiethnic cohort","volume":"111","author":"Setiawan","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2948","article-title":"Diabetes, weight change, and pancreatic cancer risk","volume":"6","author":"Yuan","year":"2020","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2023.07.001","article-title":"Risk of pancreatic cancer in people with new-onset diabetes: A Danish nationwide population-based cohort study","volume":"23","author":"Jensen","year":"2023","journal-title":"Pancreatology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf177","article-title":"IDF diabetes atlas 11th edition 2025: global prevalence and projections for 2050","volume":"41","author":"Duncan","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-018-0197-8","article-title":"Pancreatic cancer and diabetes mellitus","volume":"16","author":"Sharma","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf304","article-title":"Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality","volume":"46","author":"Wei","year":"2025","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(08)70337-1","article-title":"New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer","volume":"10","author":"Pannala","year":"2009","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100155","DOI":"10.1016\/j.esmoop.2021.100155","article-title":"Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)\/Associazione Medici Diabetologi (AMD)\/Societ\u00e0 Italiana Endocrinologia (SIE)\/Societ\u00e0 Italiana Farmacologia (SIF) multidisciplinary consensus position paper","volume":"6","author":"Gallo","year":"2021","journal-title":"ESMO Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70311","article-title":"New-onset prediabetes\/diabetes worsens overall survival in patients with cancer: A real-world retrospective cohort study","author":"Winn","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1733839100","article-title":"Effectiveness of diabetes mellitus screening recommendations","volume":"100","author":"Dallo","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae844","article-title":"A research roadmap to address the heterogeneity of diabetes and advance precision medicine","volume":"110","author":"Franks","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1543112","article-title":"Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research","volume":"16","author":"Moreland","year":"2025","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"102367","DOI":"10.1016\/j.xcrm.2025.102367","article-title":"Phenotypic heterogeneity of type 2 diabetes and risks of all-cause and cause-specific mortality","volume":"6","author":"Qiu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"38585","DOI":"10.1038\/s41598-025-22556-4","article-title":"Clinical and laboratory characteristics of novel diabetes subgroups: A systematic review and meta-analysis","volume":"15","author":"Ao","year":"2025","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2337\/dci25-0013","article-title":"The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment-2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum","volume":"68","author":"Evans-Molina","year":"2025","journal-title":"Diabetologia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2003","article-title":"Cost and cost-effectiveness of large-scale screening for type 1 diabetes in colorado","volume":"43","author":"McQueen","year":"2020","journal-title":"Diabetes Care"},{"key":"B42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/dom.16522","article-title":"Health economic considerations of screening for early type 1 diabetes","author":"Rewers","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e2538031","DOI":"10.1001\/jamanetworkopen.2025.38031","article-title":"Cost-effectiveness of biomarker-associated early pancreatic cancer detection in new-onset diabetes","volume":"8","author":"Stefanova","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf319","article-title":"Pancreatic cancer screening in new-onset and deteriorating diabetes: preliminary results from the PANDOME study","volume":"111","author":"Frank","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jso.28044","article-title":"New onset diabetes in pancreatic adenocarcinoma does not correlate with molecular subtype","volume":"131","author":"Trembath","year":"2025","journal-title":"J Surg Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.34172\/hpp.2020.18","article-title":"Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis","volume":"10","author":"Mobasseri","year":"2020","journal-title":"Health Promot Perspect"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00223-4","article-title":"Type 1 diabetes","volume":"401","author":"Quattrin","year":"2023","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/ng.3353","article-title":"Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk","volume":"47","author":"Hu","year":"2015","journal-title":"Nat Genet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603571","article-title":"Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis","volume":"96","author":"Stevens","year":"2007","journal-title":"Br J Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3884-9","article-title":"Cancer incidence in persons with type 1 diabetes: a five-country study of 9, 000 cancers in type 1 diabetic individuals","volume":"59","author":"Carstensen","year":"2016","journal-title":"Diabetologia"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)61032-X","article-title":"Type 2 diabetes: principles of pathogenesis and therapy","volume":"365","author":"Stumvoll","year":"2005","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J\u00a0Epidemiol Glob Health"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602619","article-title":"Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies","volume":"92","author":"Huxley","year":"2005","journal-title":"Br J Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2260","article-title":"Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c)","volume":"28","author":"Ewald","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0542","article-title":"Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (Type 3c): A retrospective cohort study","volume":"40","author":"Woodmansey","year":"2017","journal-title":"Diabetes Care"},{"key":"B58","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41598-022-26411-8","article-title":"Incidence and risk of pancreatic cancer in patients with chronic pancreatitis: defining the optimal subgroup for surveillance","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"B59","volume-title":"National Diabetes Audit Core Report 1: Care processes and treatment targets 2023-24, underlying data","year":"2024"},{"key":"B60","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/MPA.0b013e3182592c96","article-title":"Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers","volume":"42","author":"Aggarwal","year":"2013","journal-title":"Pancreas"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2337\/db16-1477","article-title":"Diabetes, pancreatogenic diabetes, and pancreatic cancer","volume":"66","author":"Andersen","year":"2017","journal-title":"Diabetes"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05245-x","article-title":"Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia","volume":"63","author":"Esser","year":"2020","journal-title":"Diabetologia"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.08.018","article-title":"A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice","volume":"145","author":"Philip","year":"2013","journal-title":"Gastroenterology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1116-7","article-title":"Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause","volume":"51","author":"Taylor","year":"2008","journal-title":"Diabetologia"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.3390\/cancers13205067","article-title":"Obesity and pancreatic cancer: insight into mechanisms","volume":"13","author":"Eibl","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1986","article-title":"Lipocalin-2 promotes pancreatic ductal adenocarcinoma by regulating inflammation in the tumor microenvironment","volume":"77","author":"Gomez-Chou","year":"2017","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.3390\/cancers12071849","article-title":"The role of dysfunctional adipose tissue in pancreatic cancer: A molecular perspective","volume":"12","author":"Brocco","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.02.005","article-title":"High glucose triggers nucleotide imbalance through O-glcNAcylation of key enzymes and induces KRAS mutation in pancreatic cells","volume":"29","author":"Hu","year":"2019","journal-title":"Cell Metab"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.2174\/1871520621666210201095613","article-title":"Hyperglycemia promotes pancreatic cancer initiation and progression by activating the wnt\/\u03b2-catenin signaling pathway","volume":"21","author":"Chen","year":"2021","journal-title":"Anticancer Agents Med Chem"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02106-9","article-title":"Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP\/TAZ-Hedgehog signalling axis in pancreatic cancer","volume":"128","author":"Liu","year":"2023","journal-title":"Br J Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1042\/CS20090399","article-title":"Insulin resistance and hyperinsulinaemia in the development and progression of cancer","volume":"118","author":"Godsland","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1101\/2022.05.06.490845","article-title":"Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation","volume":"35","author":"Zhang","year":"2023","journal-title":"Cell Metab"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800800841","article-title":"Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer","volume":"80","author":"Permert","year":"1993","journal-title":"Br J Surg"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb02377.x","article-title":"The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting","volume":"39","author":"Cotterill","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-018-0806-0","article-title":"Insulin\/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer","volume":"17","author":"Mutgan","year":"2018","journal-title":"Mol Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.039","article-title":"Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus","volume":"134","author":"Pannala","year":"2008","journal-title":"Gastroenterology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001300","article-title":"Pathogenesis of pancreatic cancer-related diabetes mellitus: quo vadis","volume":"48","author":"Korc","year":"2019","journal-title":"Pancreas"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2022","article-title":"Pancreatic cancer-derived exosomes cause paraneoplastic \u03b2-cell dysfunction","volume":"21","author":"Javeed","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e201900573","DOI":"10.26508\/lsa.201900573","article-title":"Pancreatic cancer triggers diabetes through TGF-\u03b2-mediated selective depletion of islet \u03b2-cells","volume":"3","author":"Parajuli","year":"2020","journal-title":"Life Sci Alliance"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.49","article-title":"New insights into pancreatic cancer-induced paraneoplastic diabetes","volume":"10","author":"Sah","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3390\/biomedicines12081653","article-title":"Remnant pancreas volume affects new-onset impaired glucose homeostasis secondary to pancreatic cancer","volume":"12","author":"Yang","year":"2024","journal-title":"Biomedicines"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.642041","article-title":"Insulin-like growth factor 2 overexpression induces \u03b2-cell dysfunction and increases beta-cell susceptibility to damage","volume":"290","author":"Casellas","year":"2015","journal-title":"J Biol Chem"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2018.33.1","article-title":"The role of inflammation in diabetes: current concepts and future perspectives","volume":"14","author":"Tsalamandris","year":"2019","journal-title":"Eur Cardiol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nature04870","article-title":"Nuclear factor-kappaB in cancer development and progression","volume":"441","author":"Karin","year":"2006","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06685-2","article-title":"IL-1\u03b2+ macrophages fuel pathogenic inflammation in pancreatic cancer","volume":"623","author":"Caronni","year":"2023","journal-title":"Nature"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01346-4","article-title":"Sorcin can trigger pancreatic cancer-associated new-onset diabetes through the secretion of inflammatory cytokines such as serpin E1 and CCL5","volume":"56","author":"Gong","year":"2024","journal-title":"Exp Mol Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.06.024","article-title":"New-onset diabetes and pancreatic cancer","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1053\/j.gastro.2007.10.040","article-title":"Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer","volume":"134","author":"Chari","year":"2008","journal-title":"Gastroenterology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1053\/j.gastro.2018.04.025","article-title":"Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis","volume":"155","author":"Sharma","year":"2018","journal-title":"Gastroenterology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2019.03.006","article-title":"Weight change and blood glucose concentration as markers for pancreatic cancer in subjects with new-onset diabetes mellitus: A matched case-control study","volume":"19","author":"Mueller","year":"2019","journal-title":"Pancreatology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001917","article-title":"Noninvasive models screen new-onset diabetics at low risk of early-onset pancreatic cancer","volume":"50","author":"Khan","year":"2021","journal-title":"Pancreas"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.05.023","article-title":"Model to determine risk of pancreatic cancer in patients with new-onset diabetes","volume":"155","author":"Sharma","year":"2018","journal-title":"Gastroenterology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10620-020-06139-z","article-title":"Validation of the enriching new-onset diabetes for pancreatic cancer model in a diverse and integrated healthcare setting","volume":"66","author":"Chen","year":"2021","journal-title":"Dig Dis Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2021.02.001","article-title":"Validation of the ENDPAC model: Identifying new-onset diabetics at risk of pancreatic cancer","volume":"21","author":"Khan","year":"2021","journal-title":"Pancreatology"},{"key":"B98","doi-asserted-by":"publisher","first-page":"107965","DOI":"10.1016\/j.cmpb.2023.107965","article-title":"Prediction of pancreatic cancer risk in patients with new-onset diabetes using a machine learning approach based on routine biochemical parameters","volume":"244","author":"Cichosz","year":"2024","journal-title":"Comput Methods Programs Biomed"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S370158","article-title":"Application of metabolomics in various types of diabetes","volume":"15","author":"Wu","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmad004","article-title":"Identification of differential metabolites between \u2028Type 2 diabetes and postchronic pancreatitis diabetes (Type 3c) based on an untargeted metabolomics approach","volume":"54","author":"Qi","year":"2023","journal-title":"Lab Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16249","article-title":"Serum metabolomics differentiating pancreatic cancer from new-onset diabetes","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12313","article-title":"Altered profile of serum microRNAs in pancreatic cancer-associated new-onset diabetes mellitus","volume":"8","author":"Dai","year":"2016","journal-title":"J Diabetes"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0217","article-title":"Galectin-3 and S100A9: novel diabetogenic factors mediating pancreatic cancer-associated diabetes","volume":"42","author":"Liao","year":"2019","journal-title":"Diabetes Care"},{"key":"B104","doi-asserted-by":"publisher","first-page":"103802","DOI":"10.1016\/j.ebiom.2021.103802","article-title":"Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes","volume":"75","author":"Oldfield","year":"2022","journal-title":"EBioMedicine"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac670","article-title":"A reduced pancreatic polypeptide response is associated with new-onset pancreatogenic diabetes versus type 2 diabetes","volume":"108","author":"Hart","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.16.9006","article-title":"Glucagon\/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus","volume":"8","author":"Kolb","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.32","article-title":"Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles","volume":"105","author":"Huang","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.12.031","article-title":"VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress","volume":"373","author":"Kang","year":"2016","journal-title":"Cancer Lett"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037267","article-title":"New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES Trial): protocol of a prospective, multicentre observational trial","volume":"10","author":"Ill\u00e9s","year":"2020","journal-title":"BMJ Open"},{"key":"B110","doi-asserted-by":"publisher","first-page":"106659","DOI":"10.1016\/j.cct.2021.106659","article-title":"Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma","volume":"113","author":"Chari","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068010","article-title":"United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer","volume":"12","author":"Oldfield","year":"2022","journal-title":"BMJ Open"},{"key":"B112","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","article-title":"Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium","volume":"69","author":"Goggins","year":"2020","journal-title":"Gut"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.259","article-title":"Early detection of pancreatic cancer: opportunities and challenges","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1930","article-title":"Pancreatic cancer surveillance and survival of high-risk individuals","volume":"10","author":"Blackford","year":"2024","journal-title":"JAMA Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.10.014","article-title":"Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals","volume":"162","author":"Overbeek","year":"2022","journal-title":"Gastroenterology"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30106-6","article-title":"Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer","volume":"1","author":"Hart","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001169","article-title":"A prospective study to establish a new-onset diabetes cohort: from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer","volume":"47","author":"Maitra","year":"2018","journal-title":"Pancreas"},{"key":"B118","volume-title":"Identifier NCT05132244, monitoring and managing glucose levels in people with pancreatic cancer (PEGASUS)","author":"Renouf","year":"2025"},{"key":"B119","doi-asserted-by":"publisher","first-page":"e70878","DOI":"10.1002\/cam4.70878","article-title":"Assessing NODM patients for early PDAC diagnosis: incidence of NODM before PDAC diagnosis and subsequent PDAC risk","volume":"14","author":"Munigala","year":"2025","journal-title":"Cancer Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e584","DOI":"10.1097\/AS9.0000000000000584","article-title":"Prevalence of new-onset diabetes in patients undergoing pancreatic surgery and the association of glucose dysregulation with complications in pancreatic cancer","volume":"6","author":"Stott","year":"2025","journal-title":"Ann Surg Open"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2025.1645459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:42:57Z","timestamp":1768196577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2025.1645459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":120,"alternative-id":["10.3389\/fgstr.2025.1645459"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2025.1645459","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1645459"}}